UROVANT SCIENCES
Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. Our lead product candidate is vibegron, an oral, once-daily, small molecule beta-3 agonist, being developed for overactive bladder (OAB), OAB in men with benign prostatic hyperplasia (BPH) and pain associated with irritable bowel syndrome (IBS). Urovant’s second investigational product candidate, URO-902, is a novel gene therapy for patients with overactive bladder (OAB) symptoms who have failed oral pharmacologic therapy.
UROVANT SCIENCES
Industry:
Biopharma Biotechnology Health Care Medical
Founded:
2017-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.urovant.com
Total Employee:
101+
Status:
Active
Contact:
949-226-6029
Email Addresses:
[email protected]
Total Funding:
100 M USD
Technology used in webpage:
SPF Google Maps Amazon IPv6 ReCAPTCHA Microsoft Azure DNS ReCAPTCHA V2 Amazon Virginia Region Amazon Route 53 AWS Global Accelerator
Similar Organizations
Asklepios BioPharmaceutical
Asklepios BioPharmaceutical is a biotechnology company developing adeno-associated virus (AAV) gene therapies for genetic disorders.
Attralus
Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients.
Autolus
Autolus is a biopharmaceutical company focused on T-cell programming and manufacturing technology.
Cytokinetics
Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Harmony Biosciences
Harmony Biosciences is a pharmaceutical company that develops and commercializes novel therapies for rare neurological disorders.
Mainstay Medical
Mainstay Medical is a global medical device company that is developing devices to deliver innovative therapies.
Roivant Sciences
Roivant Sciences is a biopharmaceutical company focused on the development of medicines and healthcare technologies to patients.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Employees Featured
Stock Details
Investors List
Hercules Capital
Hercules Capital investment in Debt Financing - Urovant Sciences
Key Employee Changes
Official Site Inspections
http://www.urovant.com
- Host name: ec2-3-220-29-98.compute-1.amazonaws.com
- IP address: 3.220.29.98
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Urovant Sciences"
Urovant Sciences - Crunchbase Company Profile
Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. Our lead product candidate is vibegron, an oral, once-daily, small molecule beta-3 …See details»
Sumitomo Pharma Subsidiary Companies in the U.S., Including …
Apr 3, 2023 About Urovant Sciences. Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for areas of unmet need, with …See details»
Sumitovant Biopharma and Urovant Sciences Announce …
Nov 12, 2020 Information about Urovant's directors and executive officers is included in Urovant's Annual Report on Form 10-K for the year ended March 31, 2020 filed with the SEC …See details»
Urovant Sciences - LinkedIn
Urovant Sciences is now Sumitomo Pharma America (SMPA), a science-based, technology-driven biopharmaceutical company focused on delivering therapeutic and scientific …See details»
Sumitovant Completes the "Going Private" Transaction with Our ...
Print（PDF/84KB） Mar. 30, 2021 Corporate Sumitovant Completes the "Going Private" Transaction with Our Consolidated Subsidiary, Urovant. Sumitovant Biopharma Ltd., a wholly …See details»
Sumitovant Enters into an Agreement for "Going ... - Sumitomo …
Nov 13, 2020 About Urovant Sciences Ltd. Urovant is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic …See details»
Urovant Sciences Announces U.S. FDA Approval of GEMTESA
Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. The Company’s lead product, GEMTESA …See details»
Urovant Sciences - Funding, Financials, Valuation & Investors
Urovant Sciences is a global biopharmaceutical company focused on developing novel therapies for urologic conditions. Search Crunchbase. Start Free Trial . ... How much funding has this …See details»
Sumitovant Biopharma Completes Acquisition of Urovant Sciences
Mar 29, 2021 NEW YORK, LONDON, IRVINE, CA & BASEL, SWITZERLAND, March 29, 2021 (GLOBE NEWSWIRE) -- Sumitovant Biopharma and Urovant Sciences (formerly Nasdaq: …See details»
Urovant Sciences and Pierre Fabre Médicament Enter into …
Jul 5, 2022 Urovant Sciences Alana Darden Powell Vice President, Corporate Communications 949-436-3116 [email protected] Sumitovant Biopharma Maya Frutiger VP, Head of …See details»
Sumitovant Biopharma Completes Acquisition of Urovant
Mar 29, 2021 The merger agreement and the merger were approved on March 23, 2021 by the affirmative vote of holders of a majority of Urovant’s outstanding shares, and by holders of a …See details»
Urovant Sciences Enters Into Definitive Agreement for ... - Nasdaq
Nov 12, 2020 In addition, securityholders of Urovant will be able to obtain free copies of the proxy statement and Schedule 13E-3 through the Investor Relations page of Urovant’s …See details»
O’Melveny Represents Urovant in Its Sale to Sumitovant
Nov 17, 2020 FOR IMMEDIATE RELEASE SILICON VALLEY—November 16, 2020—O’Melveny advised the special committee of Urovant Sciences’ board of directors in …See details»
Urovant Sciences Provides Merger Update and Reports Third …
Feb 12, 2021 In addition, securityholders of Urovant will be able to obtain free copies of the proxy statement and Schedule 13E-3 through the Investor Relations page of Urovant’s …See details»
Sumitovant Completes the “Going Private” Transaction with Our ...
Mar 30, 2021 Urovant a consolidated subsidiary in December 2019 under the umbrella of its newly established subsidiary, Sumitovant. Based on the Transaction, Urov ant is no longer …See details»
Urovant is Getting Really Good at Urology: Specialization
Jul 26, 2022 Robinson brought considerable launch experience along with him, having previously served as president of Astellas Pharma U.S., where he led the commercial …See details»
Urovant Sciences and Sunovion Pharmaceuticals Launch Primary …
Co-promotion extends sales and market access efforts to reach primary care physicians who treat OAB patients; IRVINE, Calif. & BASEL, Switzerland & MARLBOROUGH, Mass., June 29, …See details»
As Urovant preps to launch Myrbetriq rival, it’s all systems go on …
Aug 14, 2020 Urovant may be gearing up for its first commercial launch, but that doesn’t mean it’s taking its eye off the R&D ball. As it builds its commercial organization for its overactive …See details»
Innovative Treatments, Science and Technology | Sumitomo …
Dedicated to improving the health and well-being of people around the world. We drive innovative treatments, science, and technology to address patient needs in the critical areas of psychiatry …See details»
URO-902 appears safe, efficacious in treating OAB, UUI in female …
May 13, 2022 2. Urovant Sciences to present interim data from phase 2a study of potential novel gene therapy, URO-902, and new analyses of data from phase 3 EMPOWUR extension trial of …See details»